Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: CHF6001 Dose Finding in COPD
NCT02986321Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tanimilast in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Dec 2016; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02986321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986321.